Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Catella-Lawson, Francesca, Reilly, Muredach P., Kapoor, Shiv C., Cucchiara, Andrew J., DeMarco, Susan, Tournier, Barbara, Vyas, Sachin N., FitzGerald, Garret A.·2001·New England Journal of Medicine
DOI 10.1056/nejmoa003199

Cited by (1,000)

Items 101–200 of 1,000

  1. The resolution of inflammation: the devil in the flask and in the details
    Charles Nicholas Serhan · 2011 · The FASEB Journal
  2. The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs
    Tilo Großer, Emanuela Ricciotti, Garret A. FitzGerald · 2017 · Trends in Pharmacological Sciences
  3. Rational Multitargeted Drug Design Strategy from the Perspective of a Medicinal Chemist
    Xiangqian Li, Xiaowei Li, Fang Liu, Shuo Li, Dayong Shi · 2021 · Journal of Medicinal Chemistry
  4. Pharmacodynamic of cyclooxygenase inhibitors in humans
    Marta L. Capone, Stefania Tacconelli, Luigia Di Francesco, Andrea Sacchetti, Maria Gina Sciulli, Paola Patrignani · 2006 · Prostaglandins & Other Lipid Mediators
  5. Drug Interactions
    Ingolf Cascorbi · 2012 · Deutsches Ärzteblatt international
  6. Adverse drug interactions involving common prescription and over-the-counter analgesic agents
    Elliot V. Hersh, Andrés Pinto, Paul A. Moore · 2007 · Clinical Therapeutics
  7. PharmGKB summary
    Liudmila L. Mazaleuskaya, Katherine N. Theken, Li Gong, Caroline F. Thorn, Garret A. FitzGerald, Russ Biagio Altman, Teri E. Klein · 2014 · Pharmacogenetics and Genomics
  8. Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease
    Mark J. Alberts, Deborah L. Bergman, Elise Molner, Borko D. Jovanovic, Issei Ushiwata, Jun Teruya · 2003 · Stroke
  9. Tackling ischaemic heart disease in rheumatoid arthritis
    George D. Kitas · 2003 · British journal of rheumatology
  10. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection
    Marco Cattaneo · 2007 · Journal of Thrombosis and Haemostasis
  11. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors
    C J Hawkey, Michael J. S. Langman · 2003 · Gut
  12. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine.
    M. S. Bergh, S. Budsberg · 2005 · Journal of Veterinary Internal Medicine
  13. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative
    Nienke de Graeff, Noortje Groot, Seza Özen, Despina Eleftheriou, Tadej Avčin, Brigitte Bader‐Meunier, Pavla Doležalová, Brian Michael Feldman, Isabelle Koné‐Paut, Pekka Lahdenne et al. · 2018 · Lara D. Veeken
  14. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib**The investigators had full access to the data and complete control over the design, conduct analysis, interpretation, and description of the study. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or in writing the report. The views expressed are those of the investigators alone.
    William B. White, Gerald A. Faich, JEFFREY S. BORER, Robert Makuch · 2003 · The American Journal of Cardiology
  15. Misguided drug advice for COVID-19
    Garret A. FitzGerald · 2020 · Science
  16. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High‐risk subgroups and time course of risk
    Daniel H. Solomon, Jerry Avorn, Til Stürmer‎, Robert J. Glynn, Helen Mogun, Sebastian Schneeweiß · 2006 · Arthritis & Rheumatism
  17. The Importance of Breast Adipose Tissue in Breast Cancer
    Charu Kothari, Caroline Diorio, Francine Durocher · 2020 · International Journal of Molecular Sciences
  18. Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect
    Steven R. Steinhubl, Jennifer J. Oh, Julie H. Oestreich, Suellen P. Ferraris, Richard J. Charnigo, Wendell S. Akers · 2007 · Thrombosis Research
  19. Mechanisms of aspirin resistance
    Christopher Nicholas Floyd, Albert Ferro · 2013 · Pharmacology & Therapeutics
  20. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the Working Group for Cardiovascular Pharmacotherapy of the European Society of Cardiology
    Schmidt, Morten, Lamberts, Morten, Olsen, Anne-Marie Schjerning, Fosbøll, Emil, Niessner, Alexander, Tamargo, Juan, Rosano, Giuseppe, Agewall, Stefan, Kaski, Juan Carlos, Kjeldsen, Keld et al. · 2016 · European Heart Journal
  21. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition)
    Samer Narouze, Honorio T. Benzon, David Anthony Provenzano, Asokumar Buvanendran, José Antonio De Andrés, Timothy Ray Deer, Richard L Rauck, Marc Alan Huntoon · 2017 · Regional Anesthesia & Pain Medicine
  22. The Antiplatelet Effect of Six Non-Steroidal Anti-Inflammatory Drugs and Their Pharmacodynamic Interaction With Aspirin in Healthy Volunteers
    Patrick A. Gladding, Mark W.I. Webster, Helen Farrell, Irene S. L. Zeng, Robert Park, N. Ruijine · 2008 · The American Journal of Cardiology
  23. Pain Management: Part 1: Managing Acute and Postoperative Dental Pain
    Daniel E. Becker · 2010 · Anesthesia Progress
  24. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain
    Michael Doherty, Christopher J. Hawkey, Michael A. Goulder, Iain A. Gibb, Nicola Hill, Sue Aspley, Sandie Reader · 2011 · Annals of the Rheumatic Diseases
  25. Narrative Review: Aspirin Resistance and Its Clinical Implications
    Simon Sanderson, Jon David Emery, Trevor P Baglin, Ann‐Louise Kinmonth · 2005 · Annals of Internal Medicine
  26. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19
    Carlo Perricone, Paola Triggianese, Elena Bartoloni, Giacomo Cafaro, Angelo Francesco Bonifacio, Roberto Bursi, Roberto Perricone, Roberto Gerli · 2020 · Journal of Autoimmunity
  27. RATIONAL USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. CLINICAL GUIDELINES
    Andrey E. Karateev, Evgeny Lvovich Nasonov, Vladimir T Ivashkin, A. I. Martynov, Nikolay N. Yakhno, G. P. Arutyunov, Л. И. Алексеева, Guzal R. Abuzarova, Maksim Aleksandrovich Evseev, Mikhail Lvovich Kukushkin et al. · 2018 · Rheumatology Science and Practice
  28. Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus
    Davide Capodanno, Dominick Joseph Angiolillo · 2016 · Circulation
  29. A review of the mechanisms and effectiveness of dietary polyphenols in reducing oxidative stress and thrombotic risk
    Abishek Bommannan Santhakumar, Andrew Cameron Bulmer, Indu Singh · 2013 · Journal of Human Nutrition and Dietetics
  30. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Vibeke Strand · 2007 · The Lancet
  31. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease
    John B. Standridge · 2004 · Clinical Therapeutics
  32. Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions
    Dominick Joseph Angiolillo · 2009 · Diabetes Care
  33. Prevention of non‐steroidal anti‐inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment
    Francis K.L. Chan, David Yates Graham · 2004 · Alimentary Pharmacology & Therapeutics
  34. Cardiovascular Risks of Nonsteroidal Antiinflammatory Drugs in Patients After Hospitalization for Serious Coronary Heart Disease
    Wayne A. Ray, Cristina Varas‐Lorenzo, Cecilia P. Chung, Jordi Castellsagué, Katherine T. Murray, Christoph Stein, James R. Daugherty, Patrick G. Arbogast, Luis A. García‐Rodríguez · 2009 · Circulation Cardiovascular Quality and Outcomes
  35. Platelet-Vessel Wall Interactions in Hemostasis and Thrombosis
    Rolando E. Rumbaut, Perumal Thiagarajan · 2010 · Colloquium Series on Integrated Systems Physiology From Molecule to Function
  36. An Evidence-Based Review of the Cardiovascular Risks of Nonsteroidal Anti-Inflammatory Drugs
    Michael E. Farkouh, Bruce P. Greenberg · 2009 · The American Journal of Cardiology
  37. Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance
    Scott McKee, David C. Sane, Efthymios Deliargyris · 2002 · Thrombosis and Haemostasis
  38. Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use
    Tatiane Gorski, Eduardo Lusa Cadore, Stephanie Santana Pinto, Eduardo Silva, Cleiton Silva Correa, Fernando G. Beltrami, Luiz Fernando Martins Kruel · 2009 · British Journal of Sports Medicine
  39. Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2
    Susanne Fries, Tilo Großer, Thomas S. Price, John A. Lawson, Shiv C. Kapoor, Susan DeMarco, Mathew T. Pletcher, Tim Wiltshire, Garret A. FitzGerald · 2006 · Gastroenterology
  40. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Jack Hirsh, Gordon Henry Guyatt, Gregory W. Albers, Robert A. Harrington · 2015
  41. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin
    Marc Ouellet, Denis Riendeau, M. David Percival · 2001 · Proceedings of the National Academy of Sciences
  42. Hospitalizations for Upper and Lower GI Events Associated With Traditional NSAIDs and Acetaminophen Among the Elderly in Quebec, Canada
    Rahme, Elham, Barkun, Alan, Nedjar, Hacene, Gaugris, Sabine, Watson, Douglas · 2008 · The American Journal of Gastroenterology
  43. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
    Francesca Puledda, Simona Sacco, Hans‐Christoph Diener, Messoud Ashina, Haidar M. Al‐Khazali, Sait Ashina, Rami Burstein, Eric J. Liebler, Andrea Cipriani, Min Kyung Chu et al. · 2024 · Cephalalgia
  44. Association Between Bone Mineral Density and the Use of Nonsteroidal Anti-Inflammatory Drugs and Aspirin: Impact of Cyclooxygenase Selectivity
    Laura D. Carbone, Frances A. Tylavsky, Jane A. Cauley, Tamara B. Harris, Thomas Lang, Douglas C. Bauer, Karen D. Barrow, Stephen B. Kritchevsky · 2003 · Journal of Bone and Mineral Research
  45. Thromboxane and the thromboxane receptor in cardiovascular disease
    Emer M. Smyth · 2010 · Clinical Lipidology
  46. The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin
    Carlo Patrono · 2015 · Journal of the American College of Cardiology
  47. Diet and Rheumatoid Arthritis: A Review of the Literature
    Lisa K. Stamp, Michael J. James, Leslie G. Cleland · 2005 · Seminars in Arthritis and Rheumatism
  48. Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac
    Loren Laine, Sean Curtis, Michael J. S. Langman, Dennis M. Jensen, Byron Cryer, Amarjot Kaur, Christopher Paul Cannon · 2008 · Gastroenterology
  49. Selective cyclooxygenase‐2 inhibitors: similarities and differences
    Kay Brune, Burkhard Hinz · 2004 · Scandinavian Journal of Rheumatology
  50. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease
    Adeline Vermillet, Bernadette Boval, Carine Guyetand, Thibaut Petroni, Jean‐Guillaume Dillinger, Georgios Sidéris, Claire Bal dit Sollier, Ludovic O. Drouet, Patrick Henry · 2010 · Thrombosis and Haemostasis
  51. Inflammation and atherosclerosis in rheumatoid arthritis
    Robert J. Stevens, Karen Douglas, Athanasios N. Saratzis, George D. Kitas · 2005 · Expert Reviews in Molecular Medicine
  52. Cardiovascular Effects of the Cyclooxygenase Inhibitors
    William B. White · 2007 · Hypertension
  53. Natural halloysite nanotubes modified as an aspirin carrier
    Huilin Lun, Jing Ouyang, Huaming Yang · 2014 · RSC Advances
  54. COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
    Loren Laine, William B. White, Alaa Rostom, Marc C. Hochberg · 2008 · Seminars in Arthritis and Rheumatism
  55. Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations
    Garret A. FitzGerald · 2002 · The American Journal of Cardiology
  56. The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes
    D. Angiolillo · 2012 · Drugs
  57. Nonsteroidal Anti-Inflammatory Drugs and the Heart
    Carlo Patrono, Colin Baigent · 2014 · Circulation
  58. Drug Insight: aspirin resistance—fact or fashion?
    Carlo Patrono, Bianca Rocca · 2006 · Nature Clinical Practice Cardiovascular Medicine
  59. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program
    Matthew R. Weir, RHODA S. SPERLING, Alise S. Reicin, Barry J. Gertz · 2003 · American Heart Journal
  60. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib
    Michael E. Farkouh, Jeffery Greenberg, Raban V. Jeger, K Ramanathan, Freek W.A. Verheugt, James H. Chesebro, Howard S. Kirshner, Judith S. Hochman, Christine L. Lay, Sean D. Ruland et al. · 2007 · Annals of the Rheumatic Diseases
  61. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin
    Stephen E. Kimmel, Jesse A. Berlin, Muredach P. Reilly, Jane Jaskowiak, Lori Kishel, Jesse L. Chittams, Brian L. Strom · 2004 · Journal of the American College of Cardiology
  62. Increased Superoxide and Endothelial NO Synthase Uncoupling in Blood Vessels of Bmal1-Knockout Mice
    Ciprian B. Anea, Bo Cheng, Shruti Sharma, Sanjiv Kumar, Robert W. Caldwell, Lin Yao, Mohammed Irfan Ali, Ana M. Merloiu, David W. Stepp, Stephen M. Black et al. · 2012 · Circulation Research
  63. Platelets and diabetes mellitus
    Francesca Santilli, Paola Simeone, Rossella Liani, Giovanni Davı̀ · 2015 · Prostaglandins & Other Lipid Mediators
  64. The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines
    Alan Bell, André Roussin, Raymond Cartier, Wee‐Shian Chan, James Demetrios Douketis, Anil Kumar Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu et al. · 2011 · Canadian Journal of Cardiology
  65. Paracetamol and cyclooxygenase inhibition: is there a cause for concern?
    Burkhard Hinz, Kay Brune · 2011 · Annals of the Rheumatic Diseases
  66. Aspirin Resistance and Genetic Polymorphisms
    Josie A. Cambria-Kiely, Pritesh J. Gandhi · 2002 · Journal of Thrombosis and Thrombolysis
  67. Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
    Patricia A Howard, Patrice Delafontaine · 2004 · Journal of the American College of Cardiology
  68. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease
    Giulia Renda, Stefania Tacconelli, Marta L. Capone, Daniele Sacchetta, F SANTARELLI, Maria Gina Sciulli, Marco Zimarino, M. Grana, E D’Amelio, M. Zurro · 2006 · Clinical Pharmacology & Therapeutics
  69. Managing the adverse effects of nonsteroidal anti-inflammatory drugs
    Paola Patrignani, Stefania Tacconelli, Annalisa Bruno, Carlos Sostres, Ángel Lanas · 2011 · Expert Review of Clinical Pharmacology
  70. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?
    Raúl Altman, Héctor Lucas Luciardi, Juan Antonio Muntaner, Ramón N. Herrera · 2004 · Thrombosis Journal
  71. Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs
    Peter B. Lockhart, John A. G. Gibson, Sandra Pond, Jason Leitch · 2003 · BDJ
  72. Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy
    Itsik Ben‐Dor, Neal S. Kleiman, Eli Israel Lev · 2009 · The American Journal of Cardiology
  73. Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients
    Jussi Mikkelsson, Julio C. Reséndiz, Leena E. Viiri, Janne T. Backman, Esko M Kankuri, Pekka J. Karhunen, Riitta Lassila, Aino Lepäntalo · 2006 · Thrombosis and Haemostasis
  74. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events
    James M. Scheiman, Clemence E. Hindley · 2010 · Clinical Therapeutics
  75. Scientific Statement From the American Heart Association Use of Nonsteroidal Antiinflammatory Drugs : An Update for Clinicians: A
    Kathryn A. Taubert, Elliott Marshall Antman, JOEL S. BENNETT, Alan Daugherty, Curt Daniel Furberg, Harold R. Roberts · 2007
  76. Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal
    Colin Baigent, Carlo Patrono · 2003 · Arthritis & Rheumatism
  77. The Benefit of Aspirin Chemoprophylaxis for Thromboembolism after Total Knee Arthroplasty
    Paul A. Lotke, Jess H. Lonner · 2006 · Clinical Orthopaedics and Related Research
  78. Variability in the Response to Non‐Steroidal Anti‐Inflammatory Drugs: Mechanisms and Perspectives
    Annalisa Bruno, Stefania Tacconelli, Paola Patrignani · 2013 · Basic & Clinical Pharmacology & Toxicology
  79. Aspirin: An Alternative for Pulmonary Embolism Prophylaxis After Arthroplasty?
    Ibrahim J. Raphael, Eric H. Tischler, Ronald C. Huang, Richard H. Rothman, William James Hozack, Javad Parvizi · 2013 · Clinical Orthopaedics and Related Research
  80. NSAID-induced Gastrointestinal Injury
    James M. Scheiman · 2015 · Journal of Clinical Gastroenterology
  81. Novel Nonsteroidal Antiinflammatory Drugs Possessing a Nitric Oxide Donor Diazen-1-ium-1,2-diolate Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies
    Carlos A. Velázquez, Praveen P. N. Rao, Edward E. Knaus · 2005 · Journal of Medicinal Chemistry
  82. Aspirin: Promise and Resistance in the New Millennium
    Carlo Patrono, Bianca Rocca · 2008 · Arteriosclerosis Thrombosis and Vascular Biology
  83. NSAIDs and cardiovascular risk
    Fabio Marsico, Stefania Paolillo, Pasquale Perrone Filardi · 2016 · Journal of Cardiovascular Medicine
  84. Aspirin resistance: Effect of clinical, biochemical and genetic factors
    Richard J. Fitzgerald, Munir Pirmohamed · 2011 · Pharmacology & Therapeutics
  85. Coronary Artery Stents: II. Perioperative Considerations and Management
    Lisa T. Newsome, Robert S. Weller, J. C. Gerancher, Michael A. Kutcher, Roger L. Royster · 2008 · Anesthesia & Analgesia
  86. Aspirin Loading and Release from MCM-41 Functionalized with Aminopropyl Groups via Co-condensation or Postsynthesis Modification Methods
    Ashish Datt, Izz El-Maazawi, Sarah C. Larsen · 2012 · The Journal of Physical Chemistry C
  87. Pharmacogenetics in Cardiovascular Antithrombotic Therapy
    Francisco R. Marín, Rocío Gónzález‐Conejero, Piera Capranzano, Theodore A. Bass, Vanessa Roldán, Dominick Joseph Angiolillo · 2009 · Journal of the American College of Cardiology
  88. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease
    Jean‐Guillaume Dillinger, Akram Drissa, Georgios Sidéris, Claire Bal dit Sollier, Sébastian Voicu, Stéphane Manzo‐Silberman, Damien Logeart, Ludovic O. Drouet, Patrick Henry · 2012 · American Heart Journal
  89. Aspirin and Clopidogrel Resistance
    Erin D. Michos, Reza Ardehali, Roger Scott Blumenthal, Richard A. Lange, Hossein Ardehali · 2006 · Mayo Clinic Proceedings
  90. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    JEFFREY S. BORER, Lee S. Simon · 2005 · Arthritis Research & Therapy
  91. Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use
    Daniel K. Nishijima, Shahriar Zehtabchi, Jeanette Berrong, Eric L. Legome · 2012 · The Journal of Trauma: Injury, Infection, and Critical Care
  92. Platelets and Anti-platelet Therapy
    Archibald McNicol, Sara J. Israels · 2003 · Journal of Pharmacological Sciences
  93. Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer
    Ángel Lanas · 2009 · The American Journal of the Medical Sciences
  94. Aspirin resistance: more than just a laboratory curiosity**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
    Deepak L. Bhatt · 2004 · Journal of the American College of Cardiology
  95. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population
    Elham Rahme, Dan Pettitt, Jacques LeLorier · 2002 · Arthritis & Rheumatism
  96. Effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II double-blind, randomized, placebo-controlled trial [ISRCTN98608690]
    Diederik W.J. Dippel, Eric J van Breda, H. Bart van der Worp, H. Maarten A. van Gemert, Ron J.G.M. Meijer, Laurens Jaap Kappelle, Peter J. Koudstaal, the PISA-investigators. · 2003 · BMC Cardiovascular Disorders
  97. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
    Carlo Patrono · 2024 · European Heart Journal
  98. A Clinical and Pharmacologic Review of Skeletal Muscle Relaxants for Musculoskeletal Conditions
    Frank A. Beebe, Robert L. Barkin, Stacie Barkin · 2005 · American Journal of Therapeutics
  99. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups
    Daniel H. Solomon, Robert J. Glynn, Kenneth Jay Rothman, Sebastian Schneeweiß, Soko Setoguchi, Helen Mogun, Jerry Avorn, Til Stürmer‎ · 2008 · Arthritis Care & Research
  100. Valdecoxib
    Caroline Fenton, Gillian M. Keating, Antona J. Wagstaff · 2004 · Drugs